SUPN
Supernus Pharmaceuticals IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$2.97B
P/E Ratio
—
EPS
$-0.69
Beta
0.73
52W High
$59.68
52W Low
$29.16
50-Day MA
$51.13
200-Day MA
$46.10
Dividend Yield
—
Profit Margin
-5.36%
Forward P/E
20.16
PEG Ratio
1.47
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Fundamentals
| Revenue (TTM) | $718.95M |
| Gross Profit (TTM) | $644.39M |
| EBITDA | $44.40M |
| Operating Margin | -28.90% |
| Return on Equity | -3.68% |
| Return on Assets | -2.09% |
| Revenue/Share (TTM) | $12.74 |
| Book Value | $18.48 |
| Price-to-Book | 2.74 |
| Price-to-Sales (TTM) | 4.13 |
| EV/Revenue | 3.668 |
| EV/EBITDA | 62.01 |
| Quarterly Earnings Growth (YoY) | 11.10% |
| Quarterly Revenue Growth (YoY) | 21.50% |
| Shares Outstanding | $57.58M |
| Float | $51.79M |
| % Insiders | 4.34% |
| % Institutions | 103.47% |
Historical Volatility
HV 10-Day
31.83%
HV 20-Day
35.34%
HV 30-Day
35.08%
HV 60-Day
32.29%
HV Rank
69.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($63.17 target)
1
Strong Buy4
Buy1
HoldData last updated: 4/9/2026